Menu
Preclinical studies have demonstrated that TAFA4 has considerable potential as an analgesic for the treatment of chronic postoperative and neuropathic pain.
Pain, whether chronic or acute, is a frequent condition that is challenging to treat. A lack of effective treatment is an important sociological issue with implications for the well-being of patients. Moreover, chronic pain can be debilitating and has a major effect on the morale of patients, rendering them more susceptible to depression.
Chronic postoperative pain (CPOP) is of major economic and societal concern due to the high healthcare costs and rates of absenteeism it generates. A mean of one in five patients develop Chronic postoperative pain after surgery. About 500,000 people per year suffer from Chronic postoperative pain in France, and this condition has a significant impact on the quality of life of these patients. Chronic postoperative pain remains poorly understood and is underdiagnosed, and is therefore a major problem for healthcare systems.
Chronic postoperative pain can occur in 10 to 50% of patients undergoing surgery, with 2 to 10% suffering from acute pain.
Chronic postoperative pain is one of the principal reasons for consultations at pain control centers. Amputation, breast cancer, and thoracic and herniated disc operations are the most likely causes of induced chronic pain. After lumbar pain, surgery is the second most common cause of neuropathic pain in the general population.
Millions
surgical interventions are performed around the world each year.
People
Chronic pain occurs in a mean of 20% of those undergoing surgery and is one of the major motives for consulting at a pain clinic.
Neuropathic pain is characterized by unpleasant symptoms, such as shooting pain or burning sensations, numbness, altered sensations and sensations that are very difficult to describe.
According to the International Association for the Study of Pain, neuropathic pain results directly from injury or disease affecting the somatosensory system. There is no effective long-term treatment for many patients with neuropathic pain, with some cases proving refractory to the most powerful analgesics, such as morphine . Antiepileptic drugs or antidepressants are the drugs most frequently prescribed, despite their known adverse effects.
According to the STOPNEP (Study of the Prevalence of Neuropathic Pain) epidemiological survey performed in France (source: Livre Blanc de la Douleur), the prevalence of neuropathic pain in the general population is 7% in France, and this pain is moderate to severe in 5%.
Unpleasant pain or burning sensations are experienced by 8% of the world population.
Moderate-to-severe neuropathic pain affects 5% of the population.
Discover the key milestones in the progress of the Tafalgie project
Tafalgie Therapeutics is a CNRS and AMU spin-off company engaged in biopharmaceutical research and committed to developing a new scientific approach for next-generation treatments based on a ground-breaking innovation : a mechanism of action derived from an endogenous secreted protein capable of modulating pain signals.